BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death. The company offers CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing; and HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications.
Read More…
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees54
Next Earnings Date3/11/2020 (Confirmed)
OptionableNot Optionable
BioLife Solutions (NASDAQ:BLFS) Frequently Asked Questions
What is BioLife Solutions' stock symbol?
BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."
How were BioLife Solutions' earnings last quarter?
BioLife Solutions Inc (NASDAQ:BLFS) released its quarterly earnings data on Thursday, August, 9th. The medical equipment provider reported $0.05 EPS for the quarter, beating the consensus estimate of $0.04 by $0.01. The medical equipment provider earned $5.18 million during the quarter, compared to analysts' expectations of $5.20 million. View BioLife Solutions' Earnings History.
When is BioLife Solutions' next earnings date?
How can I listen to BioLife Solutions' earnings call?
BioLife Solutions will be holding an earnings conference call on Wednesday, March 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has BioLife Solutions issued on next quarter's earnings?
BioLife Solutions updated its FY 2020
After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$50-56 million, compared to the consensus revenue estimate of $$42.95 million.
What price target have analysts set for BLFS?
6 Wall Street analysts have issued 12-month price objectives for BioLife Solutions' shares. Their forecasts range from $22.00 to $27.00. On average, they expect BioLife Solutions' share price to reach $24.33 in the next year. This suggests a possible upside of 59.1% from the stock's current price. View Analyst Price Targets for BioLife Solutions.
What is the consensus analysts' recommendation for BioLife Solutions?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioLife Solutions.
What are Wall Street analysts saying about BioLife Solutions stock?
Here are some recent quotes from research analysts about BioLife Solutions stock:
- 1. According to Zacks Investment Research, "BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. " (1/13/2020)
- 2. Maxim Group analysts commented, "On 5/9, BioLife reported 1Q19 with $5.8M in revenue, up 51% y/y and 6% sequentially, with a gross margin of 71.5%. BioLife also reported a $0.4M net profit for the quarter and ended the period with $31.8M in cash. We note that this does not include revenues from the Astero Acquisition (completed in April)." (5/22/2019)
Has BioLife Solutions been receiving favorable news coverage?
Media stories about BLFS stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. BioLife Solutions earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for BioLife Solutions.
What other stocks do shareholders of BioLife Solutions own?
Who are BioLife Solutions' key executives?
BioLife Solutions' management team includes the folowing people:
- Mr. Michael P. Rice, Pres, CEO & Director (Age 56)
- Mr. Roderick de Greef, CFO & Sec. (Age 59)
- Dr. Aby J. Mathew, Chairman of Scientific Advisory Board, Chief Technology Officer and Sr. VP (Age 47)
- Ms. Karen Foster, VP of Operations (Age 59)
- Mr. Kevin O'Donnell, VP of Cold Chain Standards, Practices & Compliance
Who are BioLife Solutions' major shareholders?
BioLife Solutions' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Casdin Capital LLC (12.07%), Russell Investments Group Ltd. (2.72%), Driehaus Capital Management LLC (2.33%), Royce & Associates LP (1.08%), Essex Investment Management Co. LLC (1.04%) and Parkman Healthcare Partners LLC (0.81%). Company insiders that own BioLife Solutions stock include Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard and Walter Villiger. View Institutional Ownership Trends for BioLife Solutions.
Which major investors are selling BioLife Solutions stock?
BLFS stock was sold by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc., Cadence Capital Management LLC, Schonfeld Strategic Advisors LLC, Perkins Capital Management Inc., Russell Investments Group Ltd., Driehaus Capital Management LLC, Bank of America Corp DE and Penbrook Management LLC. Company insiders that have sold BioLife Solutions company stock in the last year include Andrew G Hinson, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Michael Rice, Raymond W Cohen, Todd Berard and Walter Villiger. View Insider Buying and Selling for BioLife Solutions.
Which major investors are buying BioLife Solutions stock?
BLFS stock was purchased by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, Roubaix Capital LLC, Marshall Wace LLP, Bank of Montreal Can, Casdin Capital LLC, Isthmus Partners LLC, Goldman Sachs Group Inc. and Franklin Resources Inc.. View Insider Buying and Selling for BioLife Solutions.
How do I buy shares of BioLife Solutions?
Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is BioLife Solutions' stock price today?
One share of BLFS stock can currently be purchased for approximately $15.29.
MarketBeat Community Rating for BioLife Solutions (NASDAQ BLFS)
MarketBeat's community ratings are surveys of what our community members think about BioLife Solutions and other stocks. Vote "Outperform" if you believe BLFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLFS will underperform the S&P 500 over the long term. You may vote once every thirty days.
